期刊文献+

胰腺癌患者血清VEGF-C及uPA水平检测的临床意义 被引量:4

原文传递
导出
摘要 胰腺癌是一种高度恶性、预后极差的消化系统肿瘤,大多数患者在就诊时已存在局部或远处的转移。血管生成及细胞外基质( ECM)降解是肿瘤生长、浸润及转移的重要环节。血管生长因子( VEGF)及其受体在肿瘤血管生成中起重要作用[1]。尿激酶型纤溶酶原激活物( urokinose plasminogen activator,uPA)在降解ECM中起关键作用[2]。因此,本研究检测胰腺癌患者血清VEGF-C、uPA水平,分析其与临床病理及患者预后的关系,为胰腺癌的治疗和预后判断提供依据。
出处 《中华胰腺病杂志》 CAS 2016年第5期345-347,共3页 Chinese Journal of Pancreatology
  • 相关文献

参考文献10

  • 1Yoshiji H,Gomez DE,Shibuya M,et al. Expression of vascularendothelial growth factor, its receptor, and other angiogenicfactors in human breast cancer[J]. Cancer Res, 1996,56(9):2013-2016.
  • 2Lilja H, Vickers A, Scardino P. Measurements of proteases orprotease system components in blood to enhance prediction ofdisease risk or outcome in possible cancer [J]. J Clin Oncol,2007,25(4) : 347-348. D01;10.1200/jc0.2006.08.5035.
  • 3Doi Y,Yashiro M, Yamada N, et al. Significance of phospho-vascular endothelial growth factor receptor-2 expression inpancreatic cancer[J]. Cancer Sci, 2010,101 (6) : 1529-1535.DOI: 10.1111/j. 1349-7006.2010.01547. x.
  • 4Zhang B, Zhao WH, Zhou WY, et al. Expression of vascularendothelial growth factors-C and-D correlate with evidence oflymphangiogenesis and angiogenesis in pancreatic adenocarcinoma[J]. Cancer Detect Prev,2007, 31 (6) :436-442. DOI: 10.1016/j. cdp. 2007.10.016.
  • 5Schlaeppi JM, Wood JM. Targeting vascular endothelial growthfactor(VEGF) for anti-tumor therapy by anti-VEGF neutralizingmonoclonal antibodies or by VEGF receptor tyrosine-kinaseinhibitors[J]. Cancer Metastasis Rev, 1999 ,18(4) :473-481.
  • 6Spano JP, Chodkiewicz C, Maurel J, et al. Efficacy ofGemcitabine plus Axitinib compared with Gemcitabine alone inpatients with advanced pancreatic cancer: an open-labelrandomised phase II study [J]. Lancet, 2008 , 371 ( 9630 );2101-2108. DOI: 10.1016/S0140-6736(08)60661-3.
  • 7Kobayashi A, Yamaguchi T, Ishihara T, et al. Usefulness ofpi肪ma vascular endothelial growth factor in the diagnosis ofpancreatic carcinonm: differential diagnosis, tumor progression,and patient survival[J], Pancreas, 2005 ,31(1) ;74-78.
  • 8Takeuchi Y, Nakao A, Harada A, et aL Expression ofplasminogen activators and their inhibitors in human pancreaticcarcinoma : immunohistochemical study [J]. Am J Gastroenterol,1993,88(11): 1928-1933.
  • 9Longo R,Cacciamani F, Naso G, et al. Pancreatic cancer: frommolecular signature to target therapy [J]. Crit Rev OncolHematol, 2008,68(3) : 197-211. DOI; 10. 1016/j. critrevonc.2008.03.003.
  • 10Dubuisson L,Monvoisin A, Nielsen BS, et al. Expression andcellular localization of the urokinase-type plasminogen activatorand its receptor in human hepatocellular carcinoma[J]. J Pathol,2000, 190 (2): 190-195. DOI; 10. 1002/( SICI) 1096-9896(200002)190:2 < 190: :AID-PATH511 >3.0.CO;2-H.

同被引文献31

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部